Cardiff Oncology (CRDF) Income from Continuing Operations (2011 - 2026)
Cardiff Oncology (CRDF) posted Income from Continuing Operations of 64477000.0 for Q4 2025, down 436.52% sequentially from 12017735.0 in Q3 2025, and down 174.91% YoY from 86074389.84 in Q4 2024.
Cardiff Oncology (CRDF) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Income from Continuing Operations for 15 years, with the latest figure at 64477000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 174.91% year-over-year to 64477000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 113344831.0 (down 44.29% YoY) and the FY2025 annual result came in at 103118000.0, down 9.9% from the prior year.
- Income from Continuing Operations eased to 64477000.0 in Q4 2025 per CRDF's latest filing, from 12017735.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9573000.0 in Q4 2022 and troughed at 64477000.0 in Q4 2025.
- A 5-year average of 19056536.4 and a median of 14365901.5 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 406.58% in 2023, then jumped 51.64% in 2024.
- Over 5 years, Income from Continuing Operations stood at 9749000.0 in 2021, then increased by 1.81% to 9573000.0 in 2022, then sank by 406.58% to 48495000.0 in 2023, then surged by 51.64% to 23453989.0 in 2024, then tumbled by 174.91% to 64477000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 64477000.0, 12017735.0, and 18704925.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -9.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.30 Mn |
| Dec 31, 2025 | -64.48 Mn |
| Sep 30, 2025 | -12.02 Mn |
| Jun 30, 2025 | -18.70 Mn |
| Mar 31, 2025 | -18.15 Mn |
| Dec 31, 2024 | -23.45 Mn |
| Sep 30, 2024 | -14.40 Mn |
| Jun 30, 2024 | -12.91 Mn |
| Mar 31, 2024 | -27.79 Mn |
| Dec 31, 2023 | -48.50 Mn |
| Sep 30, 2023 | -10.17 Mn |
| Jun 30, 2023 | -13.92 Mn |
| Mar 31, 2023 | -12.43 Mn |
| Dec 31, 2022 | -9.57 Mn |
| Sep 30, 2022 | -9.79 Mn |
| Jun 30, 2022 | -13.94 Mn |
| Mar 31, 2022 | -14.75 Mn |
| Dec 31, 2021 | -9.75 Mn |
| Sep 30, 2021 | -14.52 Mn |
| Jun 30, 2021 | -14.33 Mn |